OD

Basware Commits To Support Electronic Invoicing In France

Retrieved on: 
Tuesday, August 1, 2023
Payment Card Industry Data Security Standard, Mercedes-Benz, EDI, Vinci, OD, VAT, DHL, AP, CII, ERP, Electronic, Dematerialization, National Forum, PDP, Investment, UBL, Risk, Machine learning, International Information Technology University, Ecosystem, AI, HP, Automation, Online shopping, Basware

PARIS, Aug. 1, 2023 /PRNewswire/ -- Basware, the leader in making AP automation and invoice processing happen, announced its Partner Dematerialization Platform (PDP) application on July 28th 2023, to support French businesses sending and receiving invoices digitally.

Key Points: 
  • Basware is committed to becoming a PDP provider to support French businesses through this significant transition.
  • With 40 years' experience working with major brands such as Vinci, HP, DHL and Mercedes-Benz, Basware is a pioneer in digitalization and electronic invoicing, present in 175 countries worldwide.
  • In France, Basware is actively involved in the roll-out of electronic invoicing and the implementation of the new reform.
  • In addition to electronic invoicing, the e-reporting function offered by Basware goes far beyond the requirements of the French mandate.

Basware Commits To Support Electronic Invoicing In France

Retrieved on: 
Tuesday, August 1, 2023
Payment Card Industry Data Security Standard, Mercedes-Benz, EDI, Vinci, OD, VAT, DHL, AP, CII, ERP, Electronic, Dematerialization, National Forum, PDP, Investment, UBL, Risk, Machine learning, International Information Technology University, Ecosystem, AI, HP, Automation, Online shopping, Basware

PARIS, Aug. 1, 2023 /PRNewswire/ -- Basware, the leader in making AP automation and invoice processing happen, announced its Partner Dematerialization Platform (PDP) application on July 28th 2023, to support French businesses sending and receiving invoices digitally.

Key Points: 
  • Basware is committed to becoming a PDP provider to support French businesses through this significant transition.
  • With 40 years' experience working with major brands such as Vinci, HP, DHL and Mercedes-Benz, Basware is a pioneer in digitalization and electronic invoicing, present in 175 countries worldwide.
  • In France, Basware is actively involved in the roll-out of electronic invoicing and the implementation of the new reform.
  • In addition to electronic invoicing, the e-reporting function offered by Basware goes far beyond the requirements of the French mandate.

Zenni Breaks Barriers Mainstreaming Migraine Lens Technology

Retrieved on: 
Monday, July 31, 2023
Online Retail, Health, Retail, Optical, Specialty, Lens, Headache, Migraine, Cover My Eyes (Pain and Heaven), GLARE, Hand, Multimedia, Research, Alliance Fiber Optic Products, Social media, LEDS, OD, Telescopic sight, David Zennie

Zenni , the world’s leading online eyewear retailer, today announced its latest technology innovation launch: FL-41 migraine lenses developed to help those with light sensitivity due to migraines, post-concussion relief and other conditions.

Key Points: 
  • Zenni , the world’s leading online eyewear retailer, today announced its latest technology innovation launch: FL-41 migraine lenses developed to help those with light sensitivity due to migraines, post-concussion relief and other conditions.
  • Backed by research, FL-41 lenses may benefit migraine sufferers, helping reduce attack frequency and alleviate symptoms of eye strain and light sensitivity.
  • “Zenni’s newest lens offering will provide many migraine sufferers with an affordable solution that actually works.
  • For more information about Zenni migraine lenses, visit Zenni.com and follow for updates on social media at @ZenniOptical.

FDA Approves XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis

Retrieved on: 
Tuesday, July 25, 2023
Parasitism, Loss, Refractive surgery, Therapy, Eyelash, OD, Overalls, Eye, Skin, NewYork-Presbyterian Hospital, Medicine, TARS, Inflammation, Doctor of Philosophy, Associate, Science, Blepharitis, Eyelid, MD, Patient, Crust punk, Irritation, Webcast, Weill Cornell Medicine, MITES, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Safety, Disease, Egg, Pharmaceutical industry, Demodex, Ophthalmology

IRVINE, Calif., July 25, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that the U.S. Food and Drug Administration (FDA) approved XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis. XDEMVY, formerly known as TP-03, is the first and only FDA approved treatment to directly target Demodex mites, the root cause of Demodex blepharitis.

Key Points: 
  • XDEMVY, formerly known as TP-03, is the first and only FDA approved treatment to directly target Demodex mites, the root cause of Demodex blepharitis.
  • Patients with Demodex blepharitis were randomized to either XDEMVY or vehicle at a 1:1 ratio and dosed twice daily in each eye over the course of 6 weeks.
  • Demodex blepharitis is characterized by redness, inflammation, missing or misdirected eyelashes, horizontal itching along the eyelid base and the presence of collarettes.
  • After the live webcast, the event will remain archived on the Tarsus website for at least 90 days.

Prevent Blindness Declares July as Dry Eye Awareness Month to Educate Public on Eye Disease that Affects more than 16 Million Americans

Retrieved on: 
Thursday, July 20, 2023
Cornea, Medicine, Risk factor, Diuretic, Diabetes, Allergy, NEI, Visual impairment, OD, Anxiety, Social media, Eye, American Academy, American Academy of Ophthalmology, Lupus, Sjögren syndrome, Computer, Graves' ophthalmopathy, Telecanthus, Patient, Risk, National Eye Institute, Health, Meibomian gland dysfunction, MGD, Rheumatoid arthritis, Personal protective equipment, Cosmetics, Ophthalmology

CHICAGO, July 20, 2023 /PRNewswire-PRWeb/ -- Nearly 16 million Americans have dry eye, according to the National Eye Institute (NEI). Dry eye occurs when there is not enough tear film produced, the tear film is not draining properly from the eye, or the tear film is not the quality needed to maintain the health of the eye. If left untreated, dry eye can cause damage to the cornea.

Key Points: 
  • In an effort to educate the public on dry eye, Prevent Blindness , the nation's leading nonprofit eye health organization, has declared July as "Dry Eye Awareness Month."
  • Patients must inform their eyecare professional of all medications they are taking in order to treat dry eye and other eye conditions effectively.
  • "Dry eye is a serious condition that may have long-term effects on eye health, if left untreated," said Jeff Todd, president and CEO of Prevent Blindness.
  • For more information on dry eye, please visit the Prevent Blindness resource page at PreventBlindness.org/understanding-dry-eye .

NovaBay Pharmaceuticals Supports National Dry Eye Awareness Month with Educational Programs and Avenova Product Promotions

Retrieved on: 
Wednesday, June 28, 2023
Cosmetics, Retail, Health, Pharmaceutical, Optical, Biotechnology, Chek, Contact, Advertising, OD, NBY, Woo, Optometry, Patient, Hygiene, NovaBay Pharmaceuticals, Air pollution, NYSE, Social media, Nursing

(NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces that it will be sponsoring dry eye educational programs and offering special promotions on its Avenova®-branded eyecare products to customers and eyecare professionals throughout July in support of National Dry Eye Awareness Month.

Key Points: 
  • (NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces that it will be sponsoring dry eye educational programs and offering special promotions on its Avenova®-branded eyecare products to customers and eyecare professionals throughout July in support of National Dry Eye Awareness Month.
  • “Over the years we have consistently heard from patients and eyecare professionals alike that managing chronic dry eye can be a challenge.
  • Recognizing that a single approach may not be sufficient to gain and sustain relief from the symptoms of dry eye, NovaBay now offers a full line of best-in-class products under the Avenova brand.
  • NovaBay offers best-in-class Avenova-branded products for each step of the standard dry-eye treatment regimen, including Avenova spray, the No.

Additional Data from Phase 4 TEPEZZA® (teprotumumab-trbw) Clinical Trial Presented at the Endocrine Society Annual Meeting Reinforces Efficacy in People with Thyroid Eye Disease (TED) Regardless of Disease Activity or Duration

Retrieved on: 
Saturday, June 17, 2023
Pharmaceutical, Optical, Health, Clinical Trials, ENDO, Exophthalmos, Orbital, Graves' ophthalmopathy, Week, OD, Diplopia, Medicine, Research, MS, Patient, CAS, Diagnosis, Cedars-Sinai Medical Center, The Rheumatoid Arthritis Quality of Life Questionnaire, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, SD, Food, Safety, Disease, TED, Pharmaceutical industry

The oral presentation at the Endocrine Society Annual Meeting (ENDO 2023) supports the efficacy and safety of TEPEZZA in TED patients regardless of disease activity or duration.

Key Points: 
  • The oral presentation at the Endocrine Society Annual Meeting (ENDO 2023) supports the efficacy and safety of TEPEZZA in TED patients regardless of disease activity or duration.
  • “Thyroid Eye Disease is a heterogenous disease, and its impact is not always immediately visible, affecting patients both physically in day-to-day activities, and mentally due to the emotional distress that accompanies the disease.
  • The mean duration of disease for TEPEZZA and placebo patients was 5.1 years (SD 1.88) and 5.4 years (SD 1.61), respectively.
  • The mean CAS for TEPEZZA and placebo patients was 0.3 (SD 0.47) and 0.5 (SD 0.51), respectively.

Dr. Denise L. Caleb Appointed as FutureSense's First Vice President and Director of the Human Capital Consulting Practice.

Retrieved on: 
Tuesday, June 6, 2023
CME, Human resources, Colorado Women's Hall of Fame, Female, OD, Creative services, Human Capital, CHRO, Organization development, DEIB, First, HRSI, Professional in Human Resources, Diversity, HR, PHR, ESG, SVP, Woman, Commerce, Management, SHRM

IRVINE, Calif., June 6, 2023 /PRNewswire-PRWeb/ -- FutureSense®, An Alliant Company, has selected Denise Caleb, Ed.D., M.Ed., CME, SHRM-CP, PHR as the First Vice President and Director of the Human Capital Consulting Practice, where she will lead the Human Resources (HR), Organizational Development (OD), Diversity Equity Inclusion and Belonging (DEIB) Strategy, and Creative Service lines of business.

Key Points: 
  • Denise L. Caleb, Ed.D., M.Ed., CME, SHRM-CP, PHR, has been appointed as the First Vice President and Director of the Human Capital Consulting Practice at FutureSense®, An Alliant Company.
  • Dr. Caleb, an acclaimed DEIB expert with over 25 years of experience in various leadership roles, will oversee the Human Resources, Organizational Development, DEIB Strategy, and Creative Service lines.
  • Prior to her role with FutureSense, Dr. Caleb served as the inaugural President of the Human Resource Standards Institute (HRSI), advancing the organization's strategic development and expansion as a start-up.
  • She also served as the SVP of Global Diversity and Inclusion External Strategy for the Human Resource Certification Institute (HRCI).

Thea Pharma Inc. Launches Preservative Freedom Coalition to Advocate for Preservative-free Eye Care

Retrieved on: 
Tuesday, May 30, 2023
Real, Habit, Education, OD, Coalition, Eye, Ophthalmology, Indifference, Apathy, MD, Patient, OTC, Health, Environment, Nursing, Thea

WALTHAM, Mass., May 30, 2023 /PRNewswire/ -- Thea Pharma Inc. ("Thea"), the U.S. subsidiary of Europe's leading independent ophthalmic-focused pharmaceutical company, Laboratoires Théa, today announced the launch of the Preservative Freedom Coalition to raise awareness of unmet needs in ocular surface disease and opportunities to pursue preservative-free topical ophthalmic medications. In addition to Thea, founding members of this company- and brand-agnostic initiative include: The Glaucoma Foundation, The Intrepid Eye Society, National Medical Association Ophthalmology Section, and Real World Ophthalmology.

Key Points: 
  • The Preservative Freedom Coalition will put the topic of preservative-free eye care in focus through education to eye care professionals and patients.
  • "The eye care industry has a long history of using preservatives in eye drops that persists to this day.
  • "The Preservative Freedom Coalition has the potential to make a significant impact on the education of the entire eye care community and to elevate the awareness of the deleterious effect of preservatives on the ocular surface."
  • "We look forward to working with colleagues across the ophthalmologic, optometric, medical, and pharmaceutical communities as part of the Preservative Freedom Coalition to achieve this shared vision."

Tarsus Launches “Don’t Freak Out. Get Checked Out.” Campaign During Healthy Vision Month to Encourage Patients with Demodex Blepharitis to Visit Eye Care Providers

Retrieved on: 
Monday, May 8, 2023
Human, Arm, Eyelash, Education, OD, Cataract, Attention, TARS, Inflammation, Science, Blepharitis, Slit lamp, Eyelid, MD, Patient, Infestation, Red, Disease, Pharmaceutical industry, Telescopic sight, Nursing, Cosmetics, Demodex

IRVINE, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the launch of “Don’t Freak Out. Get Checked Out.”, a disease education campaign designed to encourage patients who may have Demodex blepharitis to visit their eye care provider for an eyelid check. In support of Healthy Vision Month in May, the first of its kind campaign is designed to support patients on their journey to identify the cause of their eyelid discomfort.

Key Points: 
  • Get Checked Out.”, a disease education campaign designed to encourage patients who may have Demodex blepharitis to visit their eye care provider for an eyelid check.
  • In support of Healthy Vision Month in May, the first of its kind campaign is designed to support patients on their journey to identify the cause of their eyelid discomfort.
  • Demodex blepharitis is caused by an overpopulation of Demodex mites, the most common ectoparasites found in humans.
  • “Demodex blepharitis patients often complain of severe discomfort and can be extremely conscious of how their eyes feel all day.